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Abstract: 
Background: As direct-to-consumer personal genome testing (DTC-PGT) is increasingly 
available in Australia, knowledge of Australian’s perceptions and attitudes towards his 
technology is needed in order to assess the (potential) impact it might have on the Australian 
public and health care system.  
Aims: To explore the knowledge and perceptions of direct-to-consumer personal genome 
testing (DTC-PGT) in an Australian sample. 
Methods: An online survey asking about knowledge and perceptions of DTC-PGT, undertaken 
between October 2011 and April 2012, of 270 Australian residents.  Results were analysed 
using SAS.   
Results: Our study found limited consumer knowledge of, and interest in pursuing DTC-PGT in 
Australia. 93% of respondents correctly identified DTC-PGT as available to consumers directly, 
but only 40% correctly identified its availability in Australia.  When asked about the content 
and value of the information DTC-PGT provides, the majority of respondents indentified that 
DTC-PGT could provide information about one’s health and/or ancestry (82% and 74%).  
Additionally, respondents indicated they believed this information to be equally important as 
non-genetic information about one’s ancestry and health.   
Conclusion: While few respondents expressed an intention to pursue DTC-PGT (27%), the 
majority of people, irrespective of whether they wished to pursue it or not, believed that 
genetic information was as important as non-genetic information in regards to their health and 
their ancestry.  The value ascribed to genetic information suggests genetics plays a role in 
people’s lives and at this time, further qualitative research could explore the ways in which 
people might use and understand the genetic information provided by DTC-PGT.  
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Introduction 
Traditionally, people have accessed medical diagnostics and therapeutics through a health 
practitioner.  However the emergence of the Internet and other information technologies has 
profoundly changed this dynamic and consumers are now able to access sophisticated 
biotechnologies without medical assent or advice.  One of the most striking examples of this is 
direct to consumer personal genome testing (DTC-PGT). In this situation, consumers purchase 
an ‘at home’ DNA collection kit (usually a kit that collects a saliva sample) which they return to 
the company for testing.  The company usually then emails a report of the test results to the 
consumer.  This report may provide information about the consumer’s carrier status for 
several genetic conditions and risk estimates for common multi-factorial diseases, such as 
diabetes, heart disease, various cancers and Alzheimer’s disease.  Testing may also provide 
information about ancestry, including an ancient ancestor migration report, an estimate of the 
likelihood that the consumer is from a particular ethnic group and a description of whether or 
not the consumer has ancestral genetic ties to certain historical figures.  Since its introduction 
in 2007, DTC-PGT has functioned as a tool that individuals, groups (and families) can use as a 
means of accessing genetic information about themselves outside of the clinical setting. 
The emergence and consumption of DTC-PGT can be explained, at least in part, by the 
increasing impact of genetic information in health care.  It is also due to the increasing 
prominence of the notion of personalised medicine.  Both of these factors emphasise the 
importance of genetic influences on and understandings of health and illness, and of clinicians 
and consumers ‘knowing’ and acting upon this information.  DTC-PGT, it is argued, promotes 
health by providing individuals with information they need to make informed health care 
decisions (1). 
There has, however, been considerable debate about the value of the information DTC-PGT 
provides, including how it is understood and/or used by consumers. Recent studies have 
explored characteristics and motivations of early DTC-PGT adopters outside Australia, 
including how consumers interpret and act on their risk reports (2), and whether health-
related actions correspond appropriately to the genetic information received (3).  Almost all of 
this research has been done in the United States, the most prominent market to date for DTC-
PGT.  While there are growing markets in China, Korea and India (4-6), cultural similarities 
between Australia and the United States make the former body of literature the most 
appropriate source of critical commentary.  This research has also tended to focus on specific 
groups, including: ‘early adopter’ populations (7, 8), health and ‘high-tech’ company 
employees (9), social networkers (10), individuals who are affected or have a family member 
affected with a genetic condition (11-13) or individuals enrolled in particular studies to study 
the impact of genetic susceptibility testing (14).  There is currently no data regarding the 
knowledge and perceptions of DTC-PGT in any Australian population. 
We conducted an online survey between November 2011 and April 2012 to explore the 
Australian’s knowledge and perceptions of DTC-PGT and their expressed interest in pursuing 
DTC-PGT for themselves. 
Methods 
Survey Instrument and Recruitment: 
An online survey consisting of 30 questions was designed to capture a sample of the Australian 
public’s knowledge and perceptions of DTC-PGT.  The survey consisted of four sections.  
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Section one requested demographic information relating to age, gender, country of birth, 
country of residence, level of general education and education around genetics.  Section two 
asked respondents about their general knowledge of DTC-PGT, such as what does DTC-PGT 
provide information about, who is the test available to, how can the test be obtained, how 
they heard about testing and whether they believed the test was legal or available in Australia.  
Section three asked respondents about their perceptions of the value information from DTC-
PGT could provide.  The final section asked those respondents who had undergone DTC-PGT 
about their experience of DTC-PGT, while non-consumers of DTC-PGT were asked if they were 
planning on pursing DTC-PGT.  
The survey was distributed through online mailing lists to a university student and staff 
population, through online networks to patient support groups for people living with genetic 
conditions, via a consumer health information website, a science and technology website and 
through societies associated with genetic conditions in Australasia.  The survey was launched 
in November 2011 and closed at the end of April 2012, and used the online survey tool 
peoplepulse.com.au.  The survey took approximately 5 minutes to complete. As a link to the 
survey was distributed through list serves and posted on a website for individuals to access, 
there were no tracking statistics attached to the survey link – meaning that the reported 
responses are of the number of surveys commenced and completed.  The University of Sydney 
Human Research Ethics Committee approved this study and survey instrument (Approval and 
Reference #2012/2264). 
Statistical Analysis: 
Data was analysed using SAS 9.3 (SAS Institute Inc, Cary, NC, USA) using the PROC SURVEYFREQ 
procedure to calculate frequencies based on the 270 responses included for analysis.  
Demographic factors (age, gender and education level) were tested in PROC SURVEYFREQ in 
tables using adjusted Pearson chi-square analysis at a P< 0.05 level of significance. Summary 
statistics for relevant variables are reported using PROC SURVEYFREQ and are reported with 
95% confidence intervals. 
 
Results 
Demographics 
Overall, 402 surveys were commenced – of which 282 were completed.  Of these – 270 were 
completed by individuals who resided in Australia and were included in the analysis.  
Table 1 summarises the demographic data.  Respondents were categorised into three age 
groups according to characteristics that we felt may be relevant to awareness and uptake of 
DTC-PGT.  The first age group (18-31 years) was chosen to include a population demographic 
that is generally familiar with genetic concepts (for example via school science education) and 
with several of the media platforms used to promote DTC-PGT (for example, social media and 
online blogs). The second age category (32-45 years) was chosen to encompass potential 
consumers with permanent jobs, disposable incomes and still in their reproductive years.  This 
group also includes those who have completed their post-secondary or postgraduate 
education.  The final age category (46 and up) was chosen on the grounds that it was likely to 
include people who may be less interested in the implications of genetic information for their 
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own reproductive choices, but who might still have an interest in some of the information DTC-
PGT provides about future health and ancestry. 
 
Table 1: Demographic information frequency summary 
 Percentage of Respondents 
N=270 
(95% CI) 
Age 
18-31 55.9% (55.6% - 56.3%) 
32-45 20.7% (20.4% - 21.0%) 
46 and up 23.3% (23.0% - 23.6%) 
Gender 
Male 27.0% (26.8% - 27.3%) 
Female 72.9% (72.7% - 73.2%) 
Education 
Secondary Education or Less 21.4% (21.2% - 21.8%) 
Post-Secondary Education and Higher 78.5% (78.2% - 78.8%) 
 
Expressed Intention to Pursue DTC-PGT 
When asked if they planned on pursuing DTC-PGT, 73.0% (95% CI, 72.7% - 73.2%) indicated 
that they were not, while 27.0% (95% CI, 26.8% - 27.3%) said they were intending to or were 
currently having DTC-PGT done. No demographic variables – including age, gender or 
education – were predictive of an interest in pursuing DTC-PGT.  
Knowledge about DTC-PGT and its Availability 
In section two of the survey, all questions were ‘forced’ answers – without an option of ‘I don’t 
know.’  When asked what type of testing could be done using DTC-PGT, most responded that 
DTC-PGT could be used for health testing (82%; 95% CI, 81.2% - 81.8%) and ancestry testing 
(74.4%; 95% CI, 74.1% - 74.8%).  This is consistent with respondents’ expectations of the 
information provided by DTC-PGT; with most indicating that DTC-PGT would provide 
information about one’s health (particularly one’s future health) and ancestry (Table 2). 
Table 2: What information DTC-PGT provides to consumers: Survey responses to the 
question, “DTC-PGT provides genetic information to consumers.  What do you think this 
information could tell you about?”  
What the information from DTC-PGT could tell you about Frequency of Responses 
N=1174 
(95% CI) 
Your future health 89.3 (89.0 - 89.5) 
Your ancestry 84.4 (84.2 – 84.7) 
Your current state of health 64.1 (63.7 – 64.4) 
Your family 58.9 (58.5 – 59.2) 
Your future children 48.5 (48.1 – 48.9) 
Your physical appearance 35.6 (35.2 – 35.9) 
Your children 35.2 (34.8 – 35.3) 
Your personality 18.9 (18.6 – 19.2) 
NOTE: Respondents could select more than one answer. The frequency count is expressed as a 
percentage of the total number of responses, not the total number of respondents. 
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The vast majority (93.3%; 95% CI, 93.2% - 93.5%) of respondents correctly indicated that DTC-
PGT was available to anyone (as it is now), with 75.2% (95% CI, 74.9% - 75.5%) (correctly) 
indicating that consumers themselves could purchase a DTC-PGT.  It should be noted that in 
the introduction to the survey, respondents were provided with a definition of direct-to-
consumer.  Fewer respondents - 24.4% (95% CI, 24.1% - 24.8%) incorrectly believed that a 
doctor must request DTC-PGT.  Of those surveyed, 40.4% (95% CI, 40.0% - 40.7%) correctly 
thought it was available in Australia (as it is now), while 53.3% (95% CI, 53.0% - 53.7%) were 
unsure. In addition, 54.8% (95% CI, 54.5% - 55.2%) of respondents did not know if DTC-PGT 
was ‘legal’ in Australia, while 43% (95% CI, 42.6% - 43.3%) correctly believed that it was (and 
remains so).  At the time of the survey, Australians were able to access DTC-PGT online 
through providers located overseas; there was also one Australian company offering these 
tests (15). 
Perceived Value of the Information Provided by DTC-PGT 
Respondents were asked how they rated the value of the information that DTC-PGT could 
provide in terms of its importance to the individual.  Respondents were asked to indicate 
whether this data had medical, personal or familial importance (or any combination of these) 
or whether the information was simply ‘interesting.’ Respondents could choose multiple 
answers.  The frequency count is expressed as a percentage of the total number of responses, 
not the total number of respondents.  The results are summarised in Table 3.   
Table 3: Perceived value of information provided by DTC-PGT: Respondents’ answer to the 
question: “Do you think the information DTC-PGT provides is (select all that apply)”  
How do you view the importance of the information 
gained through DTC-PGT 
Frequency of Responses 
N=492 
(95% CI) 
Medically Important 37.0 (36.7 – 37.4) 
Personally Important 28.9 (28.6 – 29.2) 
Important to your family 22.6 (22.3 – 22.9) 
All the above 43.3 (43.0 – 43.7) 
A combination of the above 19.6 (19.3 – 19.9) 
None of the above 0.37 (0.36 – 0.41) 
It is just interesting information 30.4 (30.0 – 30.7) 
NOTE: Results are presented in the same manner as the options appeared to the respondents in the 
survey and respondents could select more than one answer. The frequency count is expressed as a 
percentage of the total number of responses, not the total number of respondents. 
 
Respondents were also asked how they rated the value of information provided by DTC-PGT, 
including the value of genetic health information and genetic ancestry information for 
themselves and for their family.  On a Likert scale, for genetic health information, over half of 
respondents indicated genetic health information was important for themselves (64.8%; 95% 
CI, 64.5% - 65.2%) and their family (58.1%; 95% CI, 57.8% - 58.5%).  When asked about genetic 
ancestry information, less than half of respondents found genetic ancestry information 
important for themselves (44.8%; 95% CI, 44.4% - 45.2%) and their family (38.9%; 95% CI, 
38.5% - 39.2%).  Respondents were also asked which type of information they believed was 
more important in determining their health: (i) their genetically predicted health status; or (ii) 
their health history and current health status.  The majority of respondents selected they were 
equally important (62.2%; 95% CI, 61.9% to 62.6%).  Likewise, respondents were asked which 
type of information they believed was more important in determining their ancestry – their 
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known family ancestry and stories or their genetically determined ancestry.  Again, the 
majority of respondents also selected they were equally important (53.7%; 95% CI, 53.3% to 
54.1%).   
 
Discussion 
This study provides the first empirical account of knowledge and perceptions of DTC-PGT in an 
Australian context.  Several findings from this survey are particularly interesting.  First, the 
results of this study suggest limited knowledge of, and interest in, pursuing DTC-PGT.  Second, 
when asked about the content and value of the information DTC-PGT provides, the majority of 
respondents identified that DTC-PGT could provide information about one’s health and/or 
ancestry and appeared to value this information as much as non-genetic information about 
one’s ancestry or their current/future health.   
Only 40% of respondents correctly identified that DTC-PGT is available in Australia (as it is 
now), with the majority of respondents (54.8%) being unaware whether DTC-PGT was ‘legal.’  
DTC-PGT was, and remains legal.  But while respondents appeared uncertain about the 
availability or legality of DTC-PGT, respondents knew they were (as they currently are) able to 
access this technology independently from health care providers.  The fact that respondents 
appeared to have a limited awareness of DTC-PGT is unsurprising; as at the time this survey 
was distributed (November 2011 to April 2012) there was no direct-to-consumer advertising in 
the Australian market.  However, Australian’s accessing the Internet could be exposed to 
online advertisements for these services.  Prior to and during the time in which the survey was 
conducted, there was also discussion of other types of direct-to-consumer personal genome 
tests in popular culture, such as the television show, ‘Who do you think you are?’ (16), 
newspaper articles about these tests and what they could offer to consumers (17-20) and 
radio reports (21).  While only 27% of the survey sample expressed an interest in pursuing 
DTC-PGT, the finding that more than half of respondents indicated they believed the tests to 
be informative, relevant and valuable suggests the potential for greater uptake.  The relational 
aspect of genetic information between family members who are genetically related raises the 
potential for DTC-PGT to inform and have an impact on an individual and perhaps their family.  
This impact can be in regards to their future health and/or their accepted narratives regarding 
their ancestry.  As genetic information may be understood and acted upon by individuals, 
families and groups in different ways, it is imperative that the benefits and limits of this 
information are understood, and appropriate options are available, so people are able to act 
upon this information in a meaningful way. 
There are two limitations to this study that caution against over-interpretation of this data.  
First, the data is from an online survey sent out via email lists associated with a university 
student and staff network, via genetic disease/disorder awareness societies around Australia, a 
science and technology website and through a health consumer website.  As a result, there is 
potential for selection bias to younger, educated individuals and towards individuals 
knowledgeable about genetics, genetic disorders/diseases and genetic screening/testing 
programs.  Indeed, our data tend to support this observation – with the largest proportion of 
respondents being younger (55.9% were aged 18-32) and respondents with a post-secondary 
or higher education (78.5%).  This is an over-representation, as the 2011 Australian census 
data found only 24% of the population to be individuals between 18-34 years of age, with 26% 
of those within this group attending a post-secondary institution (22).  Second, the overall 
sample size is small.  To be representative of the Australian population, a larger cross-section 
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of the public would need to be sampled.  Despite the limitations to this study, our data 
provides a preliminary view of knowledge of and perceptions of the Australian public towards 
DTC-PGT.   
As the cost of sequencing continues to fall and the understanding of the information this 
technology provides advances, the next step in genetic technologies – whole genome 
sequencing – is likely to become a feature of both clinical care and the health marketplace.  
Until such time that whole genome sequencing is a routine part of clinical care, it is likely that 
Australians who wish to know more about their genetics (but who do not have a clinical 
‘indication’) will seek this information through DTC-PGT services.  At this stage, however, it is 
unclear what the clinical, public health and social impact of DTC-PGT will be.  Although (only) 
27% of the respondents to our study expressed an intention to pursue testing (a very large 
number of people if cautiously generalised to the Australian community) it is particularly 
noteworthy that the majority of respondents, irrespective of whether or not they wished to 
pursue DTC-PGT, indicated that they believed the information provided by DTC-PGT was as 
important as one’s ancestral stories, medical history and current health status.  This apparent 
privileging of genetic information in understanding one’s self and one’s future health suggests 
that genetics has already deeply infiltrated our culture.  Further quantitative research with a 
nationally representative sample is needed to explore who might be interested in pursuing 
these tests, while qualitative research could explore the ways in which people might use and 
understand the genetic information provided by DTC-PGT.  
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